Category: NeuroSigma Inc
NeuroSigma makes progress in its bid to obtain a U.S. humanitarian device exemption for its therapy to treat a rare childhood brain disorder.
NeuroSigma still needs a humanitarian device exemption for its therapy to treat a rare childhood brain disorder, but the FDA has taken it part of the way there.
NeuroSigma is aiming to net as much as $50.2 million in its upcoming IPO, as the UCLA spinout develops a noninvasive system to treat epilepsy that proves resistant to drug regimens.
NeuroSigma aims to reap as much as $50.2 million in its upcoming initial public offering for the UCLA spinout's noninvasive system to treat drug-resistant epilepsy.
NeuroSigma plans to sell 3.6 million shares on the NASDAQ exchange for between $13 and $15 each, reserving the symbol NSIG, according to a regulatory filing.
Exo-suit maker ReWalk Robotics boosts its max offering price and epilepsy NeuroSigma registers for a $50 million initial public offering.
Two medical device makers are preparing initial public offerings for the coming weeks, breaking up a spree of biotech IPOs that have dominated the market.
California medical device maker NeuroSigma lands FDA investigational device exemption to launch Phase III studies of its epilepsy treatment in support of U.S. approval.
NeuroSigma is one step closer to bringing its epilepsy treatment to U.S. markets with FDA approval to begin its Phase III clinical studies.
Currently only available for investigational use in the U.S., NeuroSigma's Monarch eTNS system is already on the shelves in Europe and Canada. Earlier studies have shown a 50% reduction in seizures for 2/5 of epilepsy patients treated, NeuroSigma said.
CircuLite won CE Mark approval in the European Union for its Synergy heart pump; EuroZone regulators also OK NeuroSigma's Monarch trigeminal nerve stimulation device for epilepsy and depression.
The European Union granted CE Mark approval to a pair of medical device companies, CircuLite and NeuroSigma, for their technologies designed to treat heart failure, epilepsy and depression.
Boston Scientific chief financial officer Jeffrey Capello joins the board of directors at fertility treatment start up OvaScience; Covidien shuffles the deck for vascular therapies; Orgenesis names new CEO, CFO, CSO; National Standards Authority of Ireland adds 5 to certification committee; plus more.
Boston Scientific (NYSE:BSX) executive vice president and chief financial officer Jeffrey Capello joined the board of directors at OvaScience, a Boston, Mass.-based start up developing infertility treatments.
Capello began working at Boston Scientific in 2008, landing the CFO seat in 2010. He oversees the company's global finance, information systems, business development and corporate strategy functions.
Cardiosolutions Inc. drums up $3.3 million of a hoped-for$6.5 million funding round for its catheter-based mitral valve repair technology.
Cardiosolutions Inc. landed about half of what it hopes will amount to a $6.5 million fundraising round, pulling in $3.3 million from eight un-named investors, according to a regulatory filing.
The Stoughton, Mass.-based company is a spinout from contract manufacturer STD Med, which early last year bought a new, 32,000-square-foot cleanroom to house Cardiosolutions and sister firm Spirus Medical Inc.